KPT-330

DRUG4 trials

Sponsors

Karyopharm Therapeutics Inc, National University Hospital, Singapore, Dana-Farber Cancer Institute, Weill Medical College of Cornell University

Conditions

Chronic Myelogenous Leukemia (CML) in Blast CrisisDiffuse Large B-Cell LymphomaHematological MalignanciesRefractory Acute Lymphoblastic Leukemia (ALL)Refractory Acute Myelogenous Leukemia (AML)Refractory Biphenotypic LeukemiaRefractory Mixed Lineage LeukemiaRelapsed Acute Lymphoblastic Leukemia (ALL)

Phase 1

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

CompletedNCT01607892

Karyopharm Therapeutics IncHematological Malignancies

Start: 2012-07-23End: 2015-10-13Updated: 2023-01-26

Phase I Study of KPT330 in Asian Patients

CompletedNCT02078349

National University Hospital, SingaporeSolid Tumors

Start: 2014-02-28End: 2020-03-20Updated: 2020-09-10

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Active, not recruitingNCT02091245

Dana-Farber Cancer InstituteChronic Myelogenous Leukemia (CML) in Blast Crisis, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myelogenous Leukemia (AML) +6

Start: 2014-03-01End: 2026-12-01Updated: 2026-05-29

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

CompletedNCT02471911

Weill Medical College of Cornell UniversityDiffuse Large B-Cell Lymphoma

Start: 2015-12-11End: 2021-10-14Updated: 2022-04-12

Related Papers

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

BMC Medicine2022-04-0525 citations

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Blood2018-11-294 citations

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in <i>FLT3</i>-mutated acute myeloid leukemias: from concept to clinical trial

Haematologica2018-05-1749 citations

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.

2018-01-0552 citations

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Blood2017-12-04134 citations

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

Blood2017-05-04156 citations

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Blood2017-03-24147 citations

Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

Blood2016-12-0220 citations

A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia

Blood2016-12-026 citations

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Blood2016-12-025 citations

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

2016-09-2829 citations

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood2015-12-0315 citations

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Blood2015-12-03

Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells

Cancer Research2015-08-01

Abstract 2074: Selective inhibitor of nuclear export (SINE) compounds show synergistic anti-tumor activity in combination with dexamethasone in multiple myeloma

Cancer Research2015-08-01

Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.

Journal of Clinical Oncology2015-05-203 citations

Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells

Blood2014-12-06

Abstract 3810: Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) <i>in vivo</i>

Cancer Research2014-10-014 citations

A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).

Journal of Clinical Oncology2014-05-2011 citations

A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).

Journal of Clinical Oncology2014-05-206 citations

3 more papers not shown